CHARACTERIZATION OF THE MYOCARDIAL INFARCTION ENDPOINTS, IMPACT OF EVENT ADJUDICATION, AND TICAGRELOR EFFECTS IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL

In PLATO, ticagrelor compared with clopidogrel reduced the primary composite endpoint of CV death, MI (excluding silent MI), or stroke in patients with acute coronary syndromes. We explored the effect of ticagrelor on MI, including different types of MI and the impact of event adjudication. A